Literature DB >> 1864379

Site-directed mutagenesis reveals the importance of disulfide bridges and aromatic residues for structure and proliferative activity of human interleukin-4.

N Kruse1, T Lehrnbecher, W Sebald.   

Abstract

Mutant proteins (muteins) of human Interleukin-4 (IL4) were constructed by means of in vitro mutagenesis. The muteins were expressed in E. coli, submitted to a renaturation and purification protocol and analysed for biological activity. Exchange of the cysteines at either position 46 or 99 which form one of the three disulfide bridges resulted in a nearly complete loss of biological activity and an unstable protein. The exchange of tyrosine 124 also inactivated the protein, while a mutation of tyrosine 56 left some residual activity. Exchange of the other four cysteines or of the single tryptophane had smaller effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864379     DOI: 10.1016/0014-5793(91)80939-z

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Enthalpic and entropic contributions mediate the role of disulfide bonds on the conformational stability of interleukin-4.

Authors:  Daniela C Vaz; J Rui Rodrigues; Walter Sebald; Christopher M Dobson; Rui M M Brito
Journal:  Protein Sci       Date:  2006-01       Impact factor: 6.725

2.  Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding.

Authors:  A Wlodawer; A Pavlovsky; A Gustchina
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

3.  Disulfide bonds in homo- and heterodimers of EF-hand subdomains of calbindin D9k: stability, calcium binding, and NMR studies.

Authors:  S Linse; E Thulin; P Sellers
Journal:  Protein Sci       Date:  1993-06       Impact factor: 6.725

4.  Tuberculosis-induced variant IL-4 mRNA encodes a cytokine functioning as growth factor for (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-specific Vgamma2Vdelta2 T cells.

Authors:  ZhuQing Yuan; Richard Wang; Yuyang Lee; Crystal Y Chen; XingBing Yu; ZhongDao Wu; Dan Huang; Ling Shen; Zheng W Chen
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

5.  Interleukin 4 is inactivated via selective disulfide-bond reduction by extracellular thioredoxin.

Authors:  Nicholas M Plugis; Nielson Weng; Qinglan Zhao; Brad A Palanski; Holden T Maecker; Aida Habtezion; Chaitan Khosla
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-13       Impact factor: 11.205

6.  Induction of oxazolone-mediated features of atopic dermatitis in NOD-scid IL2Rγ(null) mice engrafted with human peripheral blood mononuclear cells.

Authors:  Thomas Nolte; Maryam Zadeh-Khorasani; Orkhan Safarov; Franziska Rueff; Rita Varga; Nadja Herbach; Rüdiger Wanke; Andreas Wollenberg; Thomas Mueller; Roswitha Gropp; Eckhard Wolf; Matthias Siebeck
Journal:  Dis Model Mech       Date:  2012-07-19       Impact factor: 5.758

7.  NOD-scid IL2R γnull mice engrafted with human peripheral blood mononuclear cells as a model to test therapeutics targeting human signaling pathways.

Authors:  Maryam Zadeh-Khorasani; Thomas Nolte; Thomas D Mueller; Markos Pechlivanis; Franziska Rueff; Andreas Wollenberg; Gert Fricker; Eckhard Wolf; Matthias Siebeck; Roswitha Gropp
Journal:  J Transl Med       Date:  2013-01-07       Impact factor: 5.531

8.  A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor.

Authors:  Michael Kraich; Markus Klein; Edwin Patiño; Henning Harrer; Joachim Nickel; Walter Sebald; Thomas D Mueller
Journal:  BMC Biol       Date:  2006-04-26       Impact factor: 7.431

9.  Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement.

Authors:  N Kruse; H P Tony; W Sebald
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

10.  Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation.

Authors:  N Kruse; B J Shen; S Arnold; H P Tony; T Müller; W Sebald
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.